Sutro Biopharma (STRO) Interest & Investment Income (2017 - 2025)
Sutro Biopharma (STRO) has disclosed Interest & Investment Income for 9 consecutive years, with -$782000.0 as the latest value for Q4 2025.
- Quarterly Interest & Investment Income rose 13.21% to -$782000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2025, down 74.02% year-over-year, with the annual reading at -$3.9 million for FY2025, 114.95% down from the prior year.
- Interest & Investment Income hit -$782000.0 in Q4 2025 for Sutro Biopharma, down from $2.0 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $4.9 million in Q2 2024 to a low of -$2.8 million in Q3 2022.
- Historically, Interest & Investment Income has averaged $1.1 million across 5 years, with a median of $186000.0 in 2021.
- Biggest five-year swings in Interest & Investment Income: plummeted 2657.8% in 2022 and later skyrocketed 2106.9% in 2023.
- Year by year, Interest & Investment Income stood at $96000.0 in 2021, then surged by 621.88% to $693000.0 in 2022, then tumbled by 466.52% to -$2.5 million in 2023, then surged by 64.53% to -$901000.0 in 2024, then grew by 13.21% to -$782000.0 in 2025.
- Business Quant data shows Interest & Investment Income for STRO at -$782000.0 in Q4 2025, $2.0 million in Q3 2025, and -$1.0 million in Q2 2025.